Syros Pharmaceuticals - SYRS Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year target prices for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $6.00 to $23.00. On average, they predict the company's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 1,438.8% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.

Syros Pharmaceuticals' stock was trading at $3.26 at the start of the year. Since then, SYRS shares have decreased by 72.5% and is now trading at $0.8968.
View the best growth stocks for 2022 here.

Syros Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,050,000 shares, an increase of 31.4% from the June 30th total of 1,560,000 shares. Based on an average trading volume of 841,300 shares, the short-interest ratio is currently 2.4 days. Approximately 7.6% of the company's shares are short sold.
View Syros Pharmaceuticals' Short Interest.

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our SYRS earnings forecast.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its earnings results on Monday, May, 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. The business had revenue of $5.47 million for the quarter, compared to analysts' expectations of $4.56 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 104.21% and a negative net margin of 403.99%. During the same period in the prior year, the firm earned ($0.23) EPS.

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include LGT Capital Partners LTD. (0.88%), Private Advisor Group LLC (0.08%) and Sawtooth Solutions LLC (0.07%). Insiders that own company stock include Eric R Olson, Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends.

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYRS stock can currently be purchased for approximately $0.90.

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $56.34 million and generates $23.49 million in revenue each year. The company earns $-86,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

Syros Pharmaceuticals employs 124 workers across the globe.

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.